These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31182226)

  • 1. Moyamoya disease: A retrospective study of 198 cases.
    Ma Y; Guo Q; Yan Y; Zhang Y; Lin Z; Zhang J; Wang K; Song C
    Med Clin (Barc); 2019 Dec; 153(12):441-445. PubMed ID: 31182226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical manifestations and neuroimaging characteristics of children with moyamoya disease].
    Li J; Liu R; Li ZY; Wu DF; Ma XJ; Miao JT
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Aug; 12(8):637-40. PubMed ID: 20704798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide survey on quasi-moyamoya disease in Japan.
    Hayashi K; Horie N; Izumo T; Nagata I
    Acta Neurochir (Wien); 2014 May; 156(5):935-40. PubMed ID: 24499994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disease presentation of Moyamoya angiopathy in Eastern India.
    Das S; Dubey S; Acharya M; Ghosh R; Chatterjee S; Hazra A; Lahiri D; Segupta S; Chatterjee S; Das G; Sarkar N; Ray BK; Kraemer M
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104957. PubMed ID: 32689603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Moyamoya Disease in China: Single-Center, Population-Based Study.
    Bao XY; Wang QN; Zhang Y; Zhang Q; Li DS; Yang WZ; Zhang ZS; Zong R; Han C; Duan L
    World Neurosurg; 2019 Feb; 122():e917-e923. PubMed ID: 30404059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial spin-labeling MR imaging in Moyamoya disease compared with clinical assessments and other MR imaging findings.
    Noguchi T; Kawashima M; Nishihara M; Hirai T; Matsushima T; Irie H
    Eur J Radiol; 2013 Dec; 82(12):e840-7. PubMed ID: 24055185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures.
    Khan N; Schuknecht B; Boltshauser E; Capone A; Buck A; Imhof HG; Yonekawa Y
    Acta Neurochir (Wien); 2003 Dec; 145(12):1061-71; discussion 1071. PubMed ID: 14663563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and clinical features of Moyamoya disease in Nanjing, China.
    Miao W; Zhao PL; Zhang YS; Liu HY; Chang Y; Ma J; Huang QJ; Lou ZX
    Clin Neurol Neurosurg; 2010 Apr; 112(3):199-203. PubMed ID: 20004511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moyamoya disease in China: its clinical features and outcomes.
    Duan L; Bao XY; Yang WZ; Shi WC; Li DS; Zhang ZS; Zong R; Han C; Zhao F; Feng J
    Stroke; 2012 Jan; 43(1):56-60. PubMed ID: 22020027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome and moyamoya: clinical presentation and surgical management.
    See AP; Ropper AE; Underberg DL; Robertson RL; Scott RM; Smith ER
    J Neurosurg Pediatr; 2015 Jul; 16(1):58-63. PubMed ID: 25837890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of infarction after encephaloduroarteriosynangiosis in young patients with moyamoya disease.
    Kim HG; Lee SK; Lee JD
    J Neurosurg Pediatr; 2017 Jan; 19(1):1-7. PubMed ID: 27715484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China.
    Bao XY; Duan L; Yang WZ; Li DS; Sun WJ; Zhang ZS; Zong R; Han C
    Cerebrovasc Dis; 2015; 39(2):75-81. PubMed ID: 25573764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion.
    Hayashi T; Shirane R; Fujimura M; Tominaga T
    J Neurosurg Pediatr; 2010 Jul; 6(1):73-81. PubMed ID: 20593991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization.
    Koss M; Scott RM; Irons MB; Smith ER; Ullrich NJ
    J Neurosurg Pediatr; 2013 Apr; 11(4):417-25. PubMed ID: 23373626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Magnetic resonance imaging in moyamoya disease].
    Fujita K; Shirakuni T; Kojima N; Tamaki N; Matsumoto S
    No Shinkei Geka; 1986 Mar; 14(3 Suppl):324-30. PubMed ID: 3703130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease.
    Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW
    J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moyamoya vasculopathy - Patient demographics and characteristics in the Finnish population.
    Saarela M; Mustanoja S; Pekkola J; Tyni T; Hernesniemi J; Kivipelto L; Tatlisumak T
    Int J Stroke; 2017 Jan; 12(1):90-95. PubMed ID: 27625049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
    Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
    J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and long-term outcomes of moyamoya syndrome associated with neurofibromatosis type 1.
    Han C; Yang WZ; Zhang HT; Ye T; Duan L
    J Clin Neurosci; 2015 Feb; 22(2):286-90. PubMed ID: 25443089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and disease progression in moyamoya disease patients with Graves disease.
    Chen JB; Lei D; He M; Sun H; Liu Y; Zhang H; You C; Zhou LX
    J Neurosurg; 2015 Oct; 123(4):848-55. PubMed ID: 25859801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.